Niimura et al. investigates the potential of an integrated glyco-nanovaccine (iGN) comprising gold nanoparticles conjugated with a synthetic Toll-like receptor 7 ligand, sugar chains, and peptide antigens for cancer immunotherapy. Treatment with iGN increases tumor-infiltrating CD8+ T cells and inhibits tumor growth.
- Mayumi Niimura
- Yasuhisa Sakamoto
- Toshiro Moroishi